Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of PF299804, a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Dacomitinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 10 Aug 2016 Planned End Date changed from 1 Oct 2015 to 1 Dec 2016.
- 11 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
- 11 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2015, as reported by ClinicalTrials.gov.